Free Trial
NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Price, News & Analysis

Amicus Therapeutics logo
$9.41 +0.05 (+0.53%)
As of 01/17/2025 04:00 PM Eastern

About Amicus Therapeutics Stock (NASDAQ:FOLD)

Key Stats

Today's Range
$9.21
$9.46
50-Day Range
$9.02
$10.49
52-Week Range
$8.78
$14.03
Volume
1.61 million shs
Average Volume
1.84 million shs
Market Capitalization
$2.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.88
Consensus Rating
Moderate Buy

Company Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
88th Percentile Overall Score

FOLD MarketRank™: 

Amicus Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 116th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Amicus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Amicus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Amicus Therapeutics are expected to grow in the coming year, from ($0.04) to $0.16 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amicus Therapeutics is -27.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amicus Therapeutics is -27.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Amicus Therapeutics has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Amicus Therapeutics has a P/B Ratio of 17.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Amicus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.48% of the outstanding shares of Amicus Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Amicus Therapeutics has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Amicus Therapeutics has recently decreased by 1.22%, indicating that investor sentiment is improving.
  • Dividend Yield

    Amicus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Amicus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.48% of the outstanding shares of Amicus Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Amicus Therapeutics has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Amicus Therapeutics has recently decreased by 1.22%, indicating that investor sentiment is improving.
  • News Sentiment

    Amicus Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Amicus Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    Only 3 people have searched for FOLD on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $259,862.00 in company stock.

  • Percentage Held by Insiders

    Only 2.20% of the stock of Amicus Therapeutics is held by insiders.

  • Read more about Amicus Therapeutics' insider trading history.
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Stock News Headlines

Wall St turns to THIS catalyst after Trump’s inauguration
Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger than his inauguration. As soon as January 29th…
Amicus reports preliminary FY24 revenue of $528M, consensus $526.12M
See More Headlines

FOLD Stock Analysis - Frequently Asked Questions

Amicus Therapeutics' stock was trading at $9.42 on January 1st, 2025. Since then, FOLD stock has decreased by 0.1% and is now trading at $9.41.
View the best growth stocks for 2025 here
.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The firm's revenue was up 34.0% on a year-over-year basis.

Top institutional investors of Amicus Therapeutics include Assenagon Asset Management S.A. (0.16%), Diversified Trust Co (0.03%), Inspire Investing LLC (0.01%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, David Michael Clark, Samantha Prout, Michael Raab and Margaret G Mcglynn.
View institutional ownership trends
.

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amicus Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Walt Disney (DIS), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
8/08/2024
Today
1/20/2025
Next Earnings (Estimated)
2/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
480
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$16.88
High Stock Price Target
$21.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+79.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-151,580,000.00
Pretax Margin
-13.85%

Debt

Sales & Book Value

Annual Sales
$399.36 million
Book Value
$0.55 per share

Miscellaneous

Free Float
292,232,000
Market Cap
$2.81 billion
Optionable
Optionable
Beta
0.62

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:FOLD) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners